World's First CAR-T for NMOSD Treatment, IASO Biotherapeutics' Equecabtagene Autoleucel, Receives IND Approval by NMPA

/PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative...

Related Keywords

China ,Shanghai ,Nanjing ,Jiangsu ,Neuromyelitis Optica ,Equecabtagene Autoleucel ,Wen Maxwell Wang ,China National Medical Products Administration ,Drug Evaluation ,National Medical Products Administration ,Neuromyelitis Optica Spectrum Disorder ,Cytokine Release Syndrome ,Expanded Disability Status Scale ,Chief Executive Officer ,Chief Medical Officer ,Investigator Initiated Trial ,New Drug Application ,Breakthrough Therapy Designation ,Orphan Drug Designation ,Drug Designation ,Iaso Biotherapeutics ,